Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioCryst's peramivir misses Phase II endpoint

BCRX said peramivir failed to significantly reduce median time to alleviation of symptoms vs. placebo, the primary

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE